drugset
drugset / Trial / NCT00253721

Melphalan With BBBD in Treating Patients With Brain Malignancies

NCT00253721 ↗

Phase 1 Terminated 21 enrolled OHSU Knight Cancer Institute National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving drugs directly into the arteries around the tumor may kill more tumor cells. Mannitol may open the blood vessels around the brain \[Blood-Brain Barrier Disruption (BBBD)\]and allow melphalan to be carried directly to the brain tumor. Giving melphalan together with BBBD may be an effective treatment for central nervous system cancer. PURPOSE: This phase I trial is studying side effects and best dose of melphalan when given together with mannitol in treating patients with central nervous system cancer.

Timeline

Start
1998-05
Primary completion
2015-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 4 mg/m2 Other
Subject Melphalan Small molecule 6 mg/m2 Other
Subject Melphalan Small molecule 8 mg/m2 Other
Subject Melphalan Small molecule 10 mg/m2 Other
Subject Melphalan Small molecule 12 mg/m2 Other

Indications

central nervous system neoplasm lymphoma metastatic malignant neoplasm